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Abstract
We investigated the levels of non-cholesterol sterols as predictors for the development of hyperglycemia (an increase in the
glucose area under the curve in an oral glucose tolerance test) and incident type 2 diabetes in a 5-year follow-up study of a
population-based cohort of Finnish men (METSIM Study, N = 1,050) having non-cholesterol sterols measured at baseline.
Additionally we determined the association of 538,265 single nucleotide polymorphisms (SNP) with non-cholesterol sterol
levels in a cross-sectional cohort of non-diabetic offspring of type 2 diabetes (the Kuopio cohort of the EUGENE2 Study,
N = 273). We found that in a cross-sectional METSIM Study the levels of sterols indicating cholesterol absorption were
reduced as a function of increasing fasting glucose levels, whereas the levels of sterols indicating cholesterol synthesis were
increased as a function of increasing 2-hour glucose levels. A cholesterol synthesis marker desmosterol significantly
predicted an increase, and two absorption markers (campesterol and avenasterol) a decrease in the risk of hyperglycemia
and incident type 2 diabetes in a 5-year follow-up of the METSIM cohort, mainly attributable to insulin sensitivity. A SNP of
ABCG8 was associated with fasting plasma glucose levels in a cross-sectional study but did not predict hyperglycemia or
incident type 2 diabetes. In conclusion, the levels of some, but not all non-cholesterol sterols are markers of the worsening
of hyperglycemia and type 2 diabetes.
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Introduction
Type 2 diabetes is associated with atherogenic dyslipidemia [1]
increasing the risk of cardiovascular mortality and morbidity [2].
Abnormalities in cholesterol metabolism in type 2 diabetes include
enhanced cholesterol synthesis and reduced cholesterol absorption
[3–6]. Also insulin resistance and obesity have been previously
associated with elevated cholesterol synthesis and low cholesterol
absorption in cross-sectional studies [7–10]. However, the
mechanisms underlying the association of non-cholesterol sterol
levels with hyperglycemia have remained unclear. Atherogenic
dyslipidemia predicts the development of type 2 diabetes [1], and
therefore sterols associated with cholesterol synthesis and absorp-
tion could also contribute to the risk of the development of
hyperglycemia and type 2 diabetes.
Single nucleotide polymorphisms (SNPs) in the sitosterolemia
genes ABCG5 and ABCG8, encoding the ATP-binding cassette sub-
family G member proteins, have been shown to regulate
cholesterol absorption [11–13]. These transporters actively efflux
plant sterols and, to a lesser extent cholesterol, back into the
intestinal lumen. In a previous genome-wide association study
SNPs rs4245791 and rs41360247 in/near ABCG8 were associated
with serum phytosterol levels [14]. The impact of SNPs in
ABCG5/8, and possible other, yet undiscovered SNPs on the
association between non-cholesterol sterol levels and glucose
metabolism is largely unknown.
To investigate in more detail the association of non-cholesterol
sterols with the risk of the worsening of hyperglycemia and
incident type 2 diabetes we addressed 1) the relationship of
cholesterol synthesis markers (squalene, cholestenol, lathosterol,
and desmosterol) and absorption markers (campesterol, sitosterol,
avenasterol, and cholestanol) with fasting and 2-hour glucose levels
in a cross-sectional setting, 2) the association of non-cholesterol
sterol levels as predictors for the worsening of hyperglycemia and
the development of incident type 2 diabetes in a 5-year follow-up
of the METSIM (METabolic Syndrome In Men) Study, and 3) the
role of insulin sensitivity, insulin secretion and genetic factors in
this relationship.
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Subjects and Methods
Participants and Clinical Measurements
METSIM study. Non-cholesterol sterol levels were deter-
mined in a random sample of 1,050 consequently examined men
from the population-based METSIM Study including 10,197
men. This study has been described in detail elsewhere [15].
Glucose tolerance was evaluated according to the American
Diabetes Association criteria [16]. Participants with previously
diagnosed diabetes mellitus or receiving statin or ezetimibe
medication were excluded, leaving 746 men for statistical analysis.
A total of 474 METSIM participants (64%) have been re-
examined during an ongoing follow-up study [follow-up time
5.460.3 years, mean6SD); 25.1% with normal glucose tolerance,
51.3% with isolated impaired fasting (IFG) glucose, 3.6% with
isolated impaired glucose tolerance (IGT), 12.1% with IFG and
IGT, and 7.9% with incident type 2 diabetes]. Body mass index
(BMI) was calculated as weight (kg) divided by the height (m)
squared. Ethical Approval The study was approved by the Ethics
Committee of the University of Kuopio and Kuopio University
Hospital, conducted in accordance with the principles of the
Declaration of Helsinki, and all study participants gave written
informed consent.
Kuopio cohort of the EUGENE2 study. The participants
were healthy, non-diabetic offspring of patients with type 2
diabetes, as previously described in detail [17]. The probands were
randomly selected among type 2 diabetic patients living in the
region of Kuopio, Finland. One of the parents had to have type 2
diabetes and the other parent normal glucose tolerance in an
OGTT. Altogether 273 offspring (128 males, 145 females) were
included in the current study aiming to identify SNPs regulating
sterol levels. Ethical Approval The study was approved by the Ethics
Committee of the University of Kuopio and Kuopio University
Hospital, conducted in accordance with the principles of the
Declaration of Helsinki, and all study participants gave written
informed consent.
Sterol and Lipid Measurements
The methods to measure sterol and lipid levels have been
described in detail elsewhere [7]. Briefly, serum cholesterol,
cholesterol precursors (squalene, cholestenol, lathosterol, and
desmosterol), campesterol, sitosterol and avenasterol (plant sterols),
and cholestanol, a metabolite of cholesterol, were quantified from
non-saponifiable serum material by capillary gas chromatography
(Agilent 6890N Network GC System, Agilent Technologies,
Wilmington, DE) equipped with a 50 m long Ultra 2 capillary
column (5% Phenyl-methyl siloxane) (Agilent Technologies,
Wilmington, DE) [18]. a-cholestane was used as the internal
standard. The inter-assay coefficients of variation for sterols at
relevant concentrations were as follows: cholesterol 3.2%, choles-
tanol 2.7%, desmosterol 6.0%, lathosterol 3.7%, campesterol
1.8%, sitosterol 2.4%, and avenasterol 4.1%, respectively.
External quality control samples were run and analyzed with
every 25 study samples. The serum values were expressed as
102 mmol/mmol of cholesterol (called ratio in the text) by dividing
non-cholesterol sterol concentrations with the cholesterol value of
the same GC run in order to eliminate the changing concentra-
tions of sterol transporters, mainly LDL. The ratios to cholesterol
of serum cholesterol precursors reflect whole-body cholesterol
synthesis and those of plant sterols and cholestanol cholesterol
absorption.
Insulin Sensitivity and Insulin Secretion Indices
Matsuda index of insulin sensitivity (ISI) was calculated as
previously reported [15]. An index of early-phase insulin secretion
during an OGTT, InsAUC0–30/GluAUC0–30, was calculated as
(fasting insulin +30 min insulin)/(fasting glucose +30 min glucose)
(pmol/mmol) [19].
Genetic Analyses
Genotyping. Genotyping for the participants of the EU-
GENE2 Study was carried out at the Finnish Genome Center in
Helsinki, Finland. Genotyping was performed with the commer-
cial release of the Infinium HumanHap 550 k version 3 SNP
microarrays (Illumina, San Diego, CA). Briefly, 750 ng of DNA
was used in genotyping according to the manufacturer’s protocol
(Illumina). Genotyping for the METSIM Study participants was
performed using the TaqMan Allelic Discrimination Assays
(Applied Biosystems) or the Sequenom MassARRAY platform at
the University of Eastern Finland.
Genotyping quality assessment and control in the
EUGENE2 study. Software package PLINK v1.07 [20] was
used for quality assessment and control for the genotyping data.
Gender calls from X chromosome genotype data was verified to be
in concordance with the reported gender of each individual. To
verify known familial relationships and to detect not reported first-
degree cryptic relationships, pairwise identity-by-descent analysis
was performed. Individuals with genotyping call rates ,99% were
excluded. All of the 273 samples passed this criterion. Total
genotyping call rate in remaining individuals was $99.2%.
Genotypes advanced to the actual association analysis if they
passed the following quality control criteria 1) had a .95%
genotype call rate (4,201 markers failed), 2) had a minor allelic
frequency (MAF) .0.1% (18,720 markers failed) and 3) demon-
strated Hardy-Weinberg Equilibrium (HWE) with a P.161025
(575 markers failed). In addition, 317 heterozygous haploid
genotypes were set to be missing. Out of the 561,466 genotypes,
a total of 538,265 markers passed these quality control criteria. For
each genotype, summary information about MAF, HWE and call
rates were recorded, and this information was used when
evaluating marker quality for replication.
Genotype replication. Most significant SNPs from the
genome-wide association analysis were replicated in the METSIM
cohort. SNPs were selected for replication based on statistical
significance, effect size, linkage disequilibrium structure and allele
frequencies. Priority was given to genotypes that showed strong
associations with several sterol measurements. Total of 177 SNPs
were genotyped. Genotypes advanced to the association analysis if
they passed the following quality control criteria 1) had a .99%
genotype call rate (20 markers failed), 2) had a MAF .5% (30
markers failed), and 3) demonstrated HWE with a P.0.001 (13
markers failed). Out of the 177 genotypes, a total of 134 markers
passed these quality control criteria.
Genome-wide association analysis. Software package
GenABEL [21] was used for genome-wide association analysis of
the EUGENE2 data. Sterol measurements were transformed to
log10-scale to adjust for skewed distributions. To account for the
family structures in the data, Identity-by-state kinship matrix
between the subjects was calculated and then used within mixed
model score test for association in related people [22]. Gender
specific differences in the levels of non-cholesterol levels have been
previously reported [23] and higher levels of cholesterol synthesis
markers squalene, lathosterol and desmosterol were also observed
in men as compared women in the EUGENE2 Kuopio cohort
(data not shown). Therefore, gender, together with age and BMI
Sterols and Type 2 Diabetes
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were included in the analysis as covariates and the additive genetic
model was applied.
Replication analysis. PLINK was used to analyze the data
from the METSIM replication study. Sterol measurements were
transformed to log10-scale to adjust for skewed distributions.
Linear regression including age and BMI as a covariate and
assuming an additive genetic model was used.
Meta-analysis. Joint fixed-effects meta-analysis combining
results from both Stage 1 (genome-wide association analysis) and
Stage 2 (replication study) was performed using PLINK. Minor
alleles from Stage 1 analysis were used as reference alleles.
Replication of ABCG8 rs4299376 in the entire METSIM
cohort. Genotyping of rs4299376 of ABCG8 in the entire
METSIM cohort was performed with TaqMan Allelic Discrim-
ination Assay (Allied Biosystems). Call rate was 100% and the
error rate 0%.
Statistical Analysis
Statistical analyses were conducted using SPSS version 19
(SPSS, Chicago, IL). All sterol to cholesterol ratios, glucose, BMI,
insulin sensitivity index (Matsuda ISI) and insulin secretion index
(InsAUC0–30/GluAUC0–30) were log-transformed to correct for
their skewed distribution. Sterols were compared across the fasting
and 2-hour glucose categories using the general linear model.
P#0.006 (corrected for 8 tests by Bonferroni method) was
considered statistically significant. Correlations between sterol
levels and indices of insulin sensitivity and insulin secretion were
evaluated with partial correlations. Associations between baseline
sterol levels and glucose area under the curve (AUC) at follow-up
were evaluated using linear regression analysis. Associations
between baseline sterol levels and incident type 2 diabetes were
evaluated with Cox regression analysis (participants having
incident type 2 diabetes at follow-up vs. participants having
NGT/NFG and HbA1c ,6.5% at baseline and follow-up
examinations, N= 97). Incident type 2 diabetes at follow-up was
defined by the American Diabetes Association criteria [24] as
follows: fasting plasma glucose (FPG) $7.0 mmol/l or 2-h plasma
glucose (2hPG) $11.1 mmol/l or HbA1c $6.5%, or by a
physician-based diagnosis between baseline and follow-up exam-
inations and the use of anti-diabetic medication. For statistical
analyses of non-cholesterol sterols as predictors for hyperglycemia
or incident type 2 diabetes, P value adjusted for multiple
comparisons (P#0.006 corrected for 8 traits) by Bonferroni
method for considered as statistically significant. For GWAS
analysis, P value adjusted for multiple comparisons (P,661029
corrected for 8 traits) by Bonferroni method was considered to be
statistically significant. For genetic association analysis, unstan-
dardized effect sizes [B (SE)] per copy of the risk allele were
estimated by linear regression analysis adjusted for age, BMI,
smoking and physical activity, using untransformed dependent
variables. Variables not normally distributed were log-transformed
for statistical analyses.
Results
Associations of Sterols with Glucose Levels, Insulin
Sensitivity and Insulin Secretion
After the exclusion of participants with previously diagnosed
diabetes mellitus and participants on statin medication, a total of
746 men were included in statistical analyses. Their mean age was
57.6 years (SD 5.8), BMI 27.1 kg/m2 (SD 3.9), 18.8% of them
were current smokers, and 63.8% were physically active (under-
taking regular physical exercise at least once a week for $30 min).
Mean FPG at baseline was 5.6 mmol/l (SD 0.6) and 2hPG
6.1 mmol/l (SD 2.20). Levels of sterols at baseline are given in
Table S1.
As shown in Figure 1 the levels of three absorption markers,
campesterol, sitosterol and avenasterol were significantly reduced
(P,16105) as a function of increasing FPG levels, but no
significant changes were observed for cholesterol synthesis
markers. Desmosterol significantly (P,161025) and lathosterol
and cholestenol nominally (P,0.01) increased as a function of
increasing 2hPG levels, whereas the levels of absorption markers
decreased (campesterol, P,0.01).
The associations of sterol levels with insulin secretion and
insulin sensitivity are shown in Table 1. Synthesis markers, of
which desmosterol particularly, correlated inversely with Matsuda
ISI, and positively with insulin secretion. In contrast, all markers of
cholesterol absorption correlated positively with Matsuda ISI, and
cholestanol correlated inversely with insulin secretion. Partial
correlations of synthesis markers and cholestanol with insulin
secretion lost their statistical significance after the adjustment for
Matsuda, suggesting that low insulin sensitivity is the primary
mechanism explaining the association of sterols indicating
cholesterol synthesis with glucose levels. Similarly, the correlations
of the three absorption markers, campesterol, sitosterol and
avenasterol were also more significant with insulin sensitivity than
with insulin secretion.
Figure 1. Non-cholesterol sterols indicating cholesterol syn-
thesis (diamonds) and absorption (circles) in relation to
hyperglycemia, according to the categories of fasting (FPG)
and 2-hour plasma glucose (2hPG) levels (N = 746). Data points
represent unadjusted means of sterol levels in each glucose category. P
values were calculated using general linear model adjusted for age, BMI,
smoking, and physical activity: **P,0.01, ***P,1025. Individuals with
previously diagnosed diabetes and on statin or ezetimibe treatment
were excluded.
doi:10.1371/journal.pone.0067406.g001
Sterols and Type 2 Diabetes
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The correlations of sterol levels with FPG and 2hPG were
considerably weaker than those with insulin sensitivity as shown in
Table 2. Synthesis markers did not correlate significantly with
FPG levels but campesterol, sitosterol and avenasterol had
significant inverse correlations with FPG. These correlations
considerably weakened after the adjustment for both insulin
sensitivity and insulin secretion, whereas no major changes were
observed when adjusted for insulin secretion only. Results for
2hPG were quite similar with the exception of higher correlations
of synthesis markers with 2hPG than with FPG. Adjustment for all
confounding factors and additionally for insulin sensitivity and
insulin secretion abolished all statistically significant associations.
Taken together, these results provide evidence that the association
of glucose metabolism with sterols is mainly mediated by low
insulin sensitivity.
Effects of Sterol Levels on the Worsening of
Hyperglycemia and the Development of Incident Type 2
Diabetes
We first evaluated in a 5-year follow-up of the METSIM Study
the effects of baseline sterol levels as predictors of the worsening of
hyperglycemia, defined by a glucose area under the curve (Glucose
AUC) in an OGTT (measurement of glucose levels at 0, 30 and
120 min) in 474 individuals without type 2 diabetes at baseline
(Table 3). The levels of synthesis markers, cholestenol
(P=6.561024) and desmosterol (P=1.661024) significantly pre-
dicted (P#0.006) an increase in Glucose AUC after the adjustment
for age, BMI, smoking and physical activity. In contrast,
absorption markers campesterol, sitosterol and avenasterol signif-
icantly predicted a decrease in Glucose AUC at follow-up, after
the adjustment for age, BMI, smoking and physical activity. The
associations were largely attributable to low insulin sensitivity since
additional adjustment for Matsuda ISI weakened all associations
(Table 3), and abolished the association of desmosterol and
campesterol with Glucose AUC at follow-up. Additional adjust-
ment for insulin secretion, glucose AUC at baseline and total
triglycerides did not substantially alter the results.
A cholesterol synthesis marker desmosterol significantly pre-
dicted an increase, and absorption markers campesterol and
avenasterol predicted a decrease in the risk of incident type 2
diabetes (Table 4). Associations of desmosterol, campesterol and
avenasterol with incident type 2 diabetes were abolished after the
adjustment for age, BMI, smoking and physical activity.
SNPs Regulating Sterol Levels
We performed a genome-wide association study of 538,265
SNPs and non-cholesterol sterol levels in the Kuopio cohort of the
EUGENE2 study, and a targeted replication of 134 SNPs in the
METSIM cohort. Table 5 presents genome-wide significant and
Figure 2 nominally significant results (P,0.001) of a meta-analysis
of the discovery sample and the replication sample. The three
genome-wide significant SNPs were all associated with the
cholesterol absorption marker levels, rs4299376 (from
P=4.7610215 to P=4.3610219) and rs6544713 (P=2.5610215
to 3.7610219, linkage disequilibrium in European populations
with rs429976, r2 = 0.99) of ABCG8, and rs6756629 of ABCG5/
ABCG8 (from P=4.8610212 to P=1.8610217). Effect sizes,
calculated as per minor allele, were positive for the ABCG8 SNPs
and negative for rs6756629 of ABCG5/ABCG8. Genome-wide
significant SNPs (rs4299376, rs6544713, and rs6756629) were all
associated with the cholesterol absorption marker levels even after
the exclusion of participants with previously diagnosed diabetes
and those taking statin medication, and adjustment for age, gender
and BMI (Table 5). The major (sterol-decreasing) allele of the most
significant SNP, rs4299376, was associated with elevated levels of
FPG (P=0.022) in the additive model, but not with the 2hPG
(P=0.425) or Glucose AUC (P=0.144) in the cross-sectional
METSIM Study cohort (5,639 men without previously diagnosed
diabetes and without statin treatment). ABCG8 rs4299376 did not
predict the worsening of hyperglycemia in a 5-year follow-up study
(P$0.121 for association with FPG, 2hPG and Glucose AUC at
follow-up in the additive model).
Discussion
We demonstrated for the first time that non-cholesterol sterol
levels predicted the worsening of hyperglycemia and the develop-
ment of incident type 2 diabetes in a 5-year prospective follow-up
of a Finnish population-based study including 1,050 men (the
Table 1. Partial correlations of sterol levels indicating cholesterol synthesis and cholesterol absorption with insulin sensitivity and
insulin secretion adjusted for age, BMI, smoking and physical activity.
Sterol, adjusted for total cholesterol Matsuda ISI InsAUC0–30/GluAUC0–30
InsAUC0–30/GluAUC0–30 adjusted for
Matsuda ISI
r P r P r P
Synthesis markers
Squalene 20.122 0.001 0.119 0.001 0.056 0.133
Lathosterol 20.230 2.9E-10 0.175 1.9E-06 0.044 0.232
Cholestenol 20.191 1.9E-07 0.147 6.6E-05 0.040 0.278
Desmosterol 20.362 4.6E-24 0.228 4.6E-10 0.009 0.807
Absorption markers
Cholestanol 0.229 4.0E-10 20.189 2.8E-07 20.064 0.084
Campesterol 0.252 4.9E-12 20.069 0.063 0.113 0.002
Sitosterol 0.222 1.2E-09 20.067 0.070 0.091 0.014
Avenasterol 0.137 2.0E-04 20.006 0.878 0.103 0.006
Individuals with previously diagnosed diabetes or on statin or ezetimibe treatment were excluded (N= 728–730). Bold types indicate statistical significance with
P#0.006.
doi:10.1371/journal.pone.0067406.t001
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METSIM cohort). We also demonstrated that rs4299376 and
rs6544713 of ABCG8 and rs6756629 of ABCG5/8 were signifi-
cantly associated with all cholesterol absorption markers (P for
association from 4.8610212 to 3.7610219), but not with choles-
terol synthesis markers. The major allele of the most significant
SNP, rs4299376 of ABCG8, was nominally associated with elevated
levels of FPG at baseline, but did not predict the development of
hyperglycemia in a 5-year follow-up study.
Elevated cholesterol synthesis and reduced absorption have
been reported in individuals with type 2 diabetes or hyperglycemia
[3–6,8–9], and have been associated with insulin resistance [7] in
cross-sectional studies. However, none of the previous studies has
investigated the association of sterol levels in the entire range of
hyperglycemia. We showed that in a cross-sectional setting,
cholesterol synthesis markers were elevated and cholesterol
absorption markers decreased as a function of 2hPG and FPG
levels, respectively.
In our 5-year follow-up of the METSIM cohort we found that
the cholesterol synthesis markers cholestenol and desmosterol
significantly (P#0.006) predicted increases in Glucose AUC, and
desmosterol also incident type 2 diabetes. Adjustment for Matsuda
ISI alone largely abolished these associations demonstrating that
low insulin sensitivity was the major mechanism explaining the
worsening of hyperglycemia and the development of incident
diabetes. Absorption markers campesterol, sitosterol, and avenas-
terol significantly predicted a decrease in Glucose AUC, and
campesterol and avenasterol also a lower risk of incident type 2
diabetes. Statistically significant associations were abolished when
Table 3. Association between baseline sterol levels and glucose area under the curve (AUC) at the 5-year follow-up study.
Sterol, adjusted for total cholesterol B (SE) P P* P{ P`
Synthesis markers
Squalene 15.8 (54.1) 0.871 0.723 0.124 0.803
Lathosterol 142.8 (47.0) 0.002 0.140 0.879 0.259
Cholestenol 240.0 (56.0) 1.1E-05 6.5E-04 0.041 0.003
Desmosterol 376.7 (80.0) 4.2E-07 1.6E-04 0.256 0.193
Absorption markers
Cholestanol 2280.9 (92.1) 0.002 0.065 0.617 0.051
Campesterol 2209.3 (42.2) 1.7E-07 0.003 0.151 0.043
Sitosterol 2214.0 (41.0) 6.6E-08 0.002 0.049 0.037
Avenasterol 2322.8 (64.6) 1.7E-07 0.006 0.038 0.052
Linear regression analysis, adjusted for age, BMI, smoking, physical activity and additional covariates as listed below. Individuals with previously diagnosed diabetes or
with statin or ezetimibe treatment were excluded (N= 458–474). B, unstandardized beta, SE, standard error. Bold types indicate statistical significance with P#0.006.
P, unadjusted.
P*, adjusted for age, BMI, smoking, and physical activity.
P{, adjusted for age, BMI, smoking, physical activity and Matsuda ISI.
P`, adjusted for age, BMI, smoking, physical activity, Matsuda ISI, InsAUC0–30/GluAUC0–30, glucose AUC at baseline and total triglycerides.
doi:10.1371/journal.pone.0067406.t003
Table 4. Association between baseline sterol levels and newly developed type 2 diabetes in a 5-year follow-up study.
Sterol, adjusted for total cholesterol Hazard ratio (95% CI) P P* P{ P`
Synthesis markers
Squalene 1.48 (0.86–2.54) 0.153 0.253 0.368 0.446
Lathosterol 1.07 (1.01–1.13) 0.014 0.488 0.993 0.419
Cholestenol 1.45 (0.92–2.27) 0.106 0.845 0.610 0.707
Desmosterol 1.19 (1.05–1.35) 0.005 0.167 0.900 0.480
Absorption markers
Cholestanol 0.89 (0.77–1.02) 0.097 0.327 0.849 0.974
Campesterol 0.95 (0.92–0.98) 0.004 0.084 0.434 0.934
Sitosterol 0.90 (0.83–0.97) 0.008 0.090 0.253 0.548
Avenasterol 0.60 (0.42–0.87) 0.006 0.158 0.789 0.607
Cox regression analysis. Participants with newly diagnosed type 2 diabetes at follow-up (N= 33) were compared to those with NGT/NFG and HbA1c ,6.5% at baseline
and follow-up examinations (N = 97). Diabetes diagnosis was defined as FPG $7.0mmol/l, 2hPG $11.1 mmol/l and/or HbA1c $6.5%. Individuals with previously
diagnosed diabetes or with statin or ezetimibe treatment were excluded. Sterol levels are adjusted for total cholesterol and divided by 10. Bold types indicate statistical
significance with P#0.006.
P, unadjusted.
P* adjusted for age, BMI, smoking, and physical activity.
P{ adjusted for age, BMI, smoking, and physical activity and Matsuda ISI.
P` adjusted for age, BMI, smoking, and physical activity and Matsuda ISI, InsulinAUC0–30/GlucoseAUC0–30, glucose AUC at baseline, and total triglycerides.
doi:10.1371/journal.pone.0067406.t004
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adjusted for Matsuda ISI and other confounding factors. To the
best of our knowledge, this is the first prospective study
demonstrating that non-cholesterol sterols predict the worsening
of hyperglycemia and incident type 2 diabetes.
We also investigated the role of genetic factors in the association
of sterol levels with the risk of type 2 diabetes. We showed that
rs4299376 and rs6544713 (in high linkage disequilibrium with
rs4299376) of ABCG8 and rs6756629 of ABCG5/8 were very
significantly associated with plant sterols (campesterol, sitosterol
and avenasterol) and cholestanol (b from 0.038 to 0.087,
P,1610214 for rs4299376, and b from 20.046 to 20.108,
P,1610211 for rs6756629) after adjustment for age, gender and
BMI. The ATP hemitransporter proteins ABCG5 and ABCG8
are key regulators of dietary cholesterol absorption in the intestinal
lumen. SNP rs4299376 of ABCG8 has previously been associated
with LDL cholesterol level and rs6756629 of ABCG5/8 with total
cholesterol level [25,26]. Previously published GWAS identified
two SNPs of ABCG8 (rs41360247 and rs4245791) as regulators of
plant sterol (campesterol and sitosterol) levels [14]. Our results are
in agreement with these findings as SNPs identified in our study
are in close linkage equilibrium (r2 = 0.99–1.0) with the SNPs
reported earlier [14]. However, the major allele of rs4299376 of
ABCG8, which was very significantly associated with surrogate
markers of cholesterol absorption, was nominally associated with
elevated fasting glucose in 5,639 men in cross-sectional analysis of
the METSIM cohort (P=0.022), but not with the worsening of
hyperglycemia or the development of incident type 2 diabetes in
our follow-up study, probably due to a relatively small sample size
in our follow-up study.
Our study has limitations. Only Finnish men were included in
the METSIM Study, and therefore, we do not know whether our
results are applicable to women and to different ethnic or racial
groups. We had only modest power to demonstrate statistically
significant associations of gene variants with non-cholesterol sterol
levels.
In conclusion, our population-based study is the first to show
that desmosterol, marker of cholesterol synthesis, and campesterol
and avenasterol, markers of cholesterol absorption, significantly
Figure 2. SNPs associated with sterol levels (left panel) and the effect size evaluated by the standardized b coefficient from linear
regression model (right panel). Genotyping results represent a meta-analysis of 1st stage (GWAS, EUGENE2 Study) and 2nd stage of targeted
replication (METSIM Study), total N= 1,013. SNPs having an association P,0.001 are shown. Individuals with previously diagnosed diabetes and on
statin or ezetimibe treatment were excluded. P-values are adjusted for age, gender and BMI.
doi:10.1371/journal.pone.0067406.g002
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predict the worsening of hyperglycemia and incident type 2
diabetes. The predominant mechanism linking sterol metabolism
to hyperglycemia is likely to be low insulin sensitivity.
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